Pliant Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pliant Therapeutics (PLRX).

Price Target Range — 9 Quarters

Analyst Consensus — 10 Analysts

2Buy

7Hold

1Sell

Consensus RatingHold# Analysts10Avg. Consensus PT$4Upside to Avg. PT+289.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 13, 2026	Canaccord Genuity	Edward Nash	PT Cut	Hold	$4→$3
Mar 12, 2026	Piper Sandler	Yasmeen Rahimi	PT Cut	Overweight	$4→$3
Nov 7, 2025	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$3→$2
Oct 10, 2025	JP Morgan	Brian Cheng	Downgrade	Neutral→Underweight	—
Aug 8, 2025	Piper Sandler	Yasmeen Rahimi	PT Cut	Overweight	$17→$4
Mar 18, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Neutral	—
Mar 4, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Neutral	—
Mar 4, 2025	Citigroup	David Lebowitz	PT Cut	Neutral	$4→$2
Mar 4, 2025	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$4→$3
Mar 4, 2025	Cantor Fitzgerald	Pete Stavropoulos	Reinstates	Neutral	—
Mar 4, 2025	Wells Fargo	Tiago Fauth	PT Cut	Equal-Weight	$4→$3
Mar 4, 2025	Needham	Joseph Stringer	Downgrade	Buy→Hold	$10
Mar 3, 2025	Leerink Partners	Faisal Khurshid	Downgrade	Outperform→Market Perform	$33→$2
Feb 14, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Neutral	—
Feb 14, 2025	Needham	Joseph Stringer	Maintained	Buy	$10
Feb 10, 2025	JP Morgan	Eric Joseph	Downgrade	Overweight→Neutral	—
Feb 10, 2025	RBC Capital	Brian Abrahams	Downgrade	Outperform→Sector Perform	$45→$4
Feb 10, 2025	Canaccord Genuity	Edward Nash	Downgrade	Buy→Hold	$4
Feb 10, 2025	Wells Fargo	Tiago Fauth	Downgrade	Overweight→Equal-Weight	$41→$4
Feb 10, 2025	Citigroup	David Lebowitz	Downgrade	Buy→Neutral	$44→$4

Analyst Ratings News

PRO
Canaccord Genuity Maintains Hold on Pliant Therapeutics, Lowers Price Target to $3

Canaccord Genuity analyst Edward Nash maintains Pliant Therapeutics (NASDAQ:PLRX) with a Hold and lowers the price target from $4 to $3.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $3

Piper Sandler analyst Yasmeen Rahimi maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and lowers the price target from $4 to $3.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Pliant Therapeutics, Lowers Price Target to $2

RBC Capital analyst Brian Abrahams maintains Pliant Therapeutics (NASDAQ:PLRX) with a Sector Perform and lowers the price target from $3 to $2.

Benzinga Newsdesk

PRO
JP Morgan Downgrades Pliant Therapeutics to Underweight

JP Morgan analyst Brian Cheng downgrades Pliant Therapeutics (NASDAQ:PLRX) from Neutral to Underweight.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $4

Piper Sandler analyst Yasmeen Rahimi maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and lowers the price target from $17 to $4.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Pliant Therapeuticsto Neutral

HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) from Neutral to Neutral.

Benzinga Newsdesk

Pliant Therapeutics Inc

Pliant Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Canaccord Genuity Maintains Hold on Pliant Therapeutics, Lowers Price Target to $3

PRO
Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $3

PRO
RBC Capital Maintains Sector Perform on Pliant Therapeutics, Lowers Price Target to $2

PRO
JP Morgan Downgrades Pliant Therapeutics to Underweight

PRO
Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $4

PRO
HC Wainwright & Co. Reiterates Neutral on Pliant Therapeuticsto Neutral

People Also Watch

People Also Watch

Pliant Therapeutics Inc

Pliant Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCanaccord Genuity Maintains Hold on Pliant Therapeutics, Lowers Price Target to $3

PROPiper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $3

PRORBC Capital Maintains Sector Perform on Pliant Therapeutics, Lowers Price Target to $2

PROJP Morgan Downgrades Pliant Therapeutics to Underweight

PROPiper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $4

PROHC Wainwright & Co. Reiterates Neutral on Pliant Therapeuticsto Neutral

People Also Watch

People Also Watch

PRO
Canaccord Genuity Maintains Hold on Pliant Therapeutics, Lowers Price Target to $3

PRO
Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $3

PRO
RBC Capital Maintains Sector Perform on Pliant Therapeutics, Lowers Price Target to $2

PRO
JP Morgan Downgrades Pliant Therapeutics to Underweight

PRO
Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $4

PRO
HC Wainwright & Co. Reiterates Neutral on Pliant Therapeuticsto Neutral